According to Pfizer's publicly available information, both of these products are tri-specific antibodies, which are new molecular entities in the company's inflammation and immune pipelines.
According to the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), on June 13th, Pfizer's two Class 1 new drugs were approved for clinical trials, both of with are intended to treat moderate to severe atopic dermatitis in adults. According to Pfizer's public information, both of these products are tri-specific antibodies, which are new molecular entities in the company's inflammation and immune pipelines. Among them, PF-07264660 is an anti-IL-4/IL-13/IL-33 triple antibody, and PF-07275315 is an anti-IL-4/IL-13/TSLP triple antibody. Both of these products are currently in Phase 2 clinical trials globally.
According to Pfizer's public information, these two tri-specific antibodies, PF-07264660 and PF-07275315, can more effectively block the IL-4/IL-13 signaling pathway, and can have a broader effect by inhibiting TSLP production or further inhibiting pruritus through the IL-33 pathway, which is expected to provide better efficacy for the treatment of atopic dermatitis.